These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 16447120)

  • 1. Models for integrating buprenorphine therapy into the primary HIV care setting.
    Basu S; Smith-Rohrberg D; Bruce RD; Altice FL
    Clin Infect Dis; 2006 Mar; 42(5):716-21. PubMed ID: 16447120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial strategies for integrating buprenorphine into HIV care settings in the United States.
    Sullivan LE; Bruce RD; Haltiwanger D; Lucas GM; Eldred L; Finkelstein R; Fiellin DA
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S191-6. PubMed ID: 17109306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine and HIV primary care: new opportunities for integrated treatment.
    Khalsa J; Vocci F; Altice F; Fiellin D; Miller V
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S169-72. PubMed ID: 17109302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of buprenorphine/naloxone treatment into HIV clinical care: lessons from the BHIVES collaborative.
    Weiss L; Netherland J; Egan JE; Flanigan TP; Fiellin DA; Finkelstein R; Altice FL;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S68-75. PubMed ID: 21317597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The medical management of opioid dependence in HIV primary care settings.
    Lum PJ; Tulsky JP
    Curr HIV/AIDS Rep; 2006 Nov; 3(4):195-204. PubMed ID: 17089480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention.
    Altice FL; Sullivan LE; Smith-Rohrberg D; Basu S; Stancliff S; Eldred L
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S178-83. PubMed ID: 17109304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care.
    Schackman BR; Merrill JO; McCarty D; Levi J; Lubinski C
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S247-53. PubMed ID: 17109311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial.
    Lucas GM; Chaudhry A; Hsu J; Woodson T; Lau B; Olsen Y; Keruly JC; Fiellin DA; Finkelstein R; Barditch-Crovo P; Cook K; Moore RD
    Ann Intern Med; 2010 Jun; 152(11):704-11. PubMed ID: 20513828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integration of buprenorphine for substance-abuse treatment by HIV care providers.
    Friedland G; Vlahov D
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S1-2. PubMed ID: 21317588
    [No Abstract]   [Full Text] [Related]  

  • 10. Improving adherence to HIV quality of care indicators in persons with opioid dependence: the role of buprenorphine.
    Korthuis PT; Fiellin DA; Fu R; Lum PJ; Altice FL; Sohler N; Tozzi MJ; Asch SM; Botsko M; Fishl M; Flanigan TP; Boverman J; McCarty D;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S83-90. PubMed ID: 21317600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A model federal collaborative to increase patient access to buprenorphine treatment in HIV primary care.
    Cheever LW; Kresina TF; Cajina A; Lubran R
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S3-6. PubMed ID: 21317591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A trial of integrated buprenorphine/naloxone and HIV clinical care.
    Sullivan LE; Barry D; Moore BA; Chawarski MC; Tetrault JM; Pantalon MV; O'Connor PG; Schottenfeld RS; Fiellin DA
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S184-90. PubMed ID: 17109305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients.
    Kresina TF; Eldred L; Bruce RD; Francis H
    AIDS; 2005 Oct; 19 Suppl 3():S221-6. PubMed ID: 16251822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Participant characteristics and HIV risk behaviors among individuals entering integrated buprenorphine/naloxone and HIV care.
    Chaudhry AA; Botsko M; Weiss L; Egan JE; Mitty J; Estrada B; Lucas GM; Woodson T; Flanigan TP; Fiellin DA;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1():S14-21. PubMed ID: 21317589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrated program of buprenorphine in the primary care setting for HIV(+) persons in Rhode Island.
    Mitty J; Macleod C; Loewenthal H; Thompson L; Bazerman L
    Med Health R I; 2007 May; 90(5):145-7. PubMed ID: 17557657
    [No Abstract]   [Full Text] [Related]  

  • 16. Buprenorphine may boost HIV treatment.
    Kuehn BM
    JAMA; 2010 Jul; 304(3):261-3. PubMed ID: 20639555
    [No Abstract]   [Full Text] [Related]  

  • 17. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications.
    Bruce RD; Dvoryak S; Sylla L; Altice FL
    Int J Drug Policy; 2007 Aug; 18(4):326-8. PubMed ID: 17689382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine in primary HIV care clinics: a big pill to swallow.
    Lucas GM
    Hopkins HIV Rep; 2004 Jul; 16(4):5-7. PubMed ID: 15386835
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV provider endorsement of primary care buprenorphine treatment: a vignette study.
    Kunins HV; Sohler NL; Roose RJ; Cunningham CO
    Fam Med; 2009; 41(10):722-8. PubMed ID: 19882396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.